| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $15...
																	Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $115 to $170.
																	BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $140 to $165.
																	
																	GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.42 by ...
																	GeneDx Holdings (NASDAQ:WGS) raises FY2025 sales outlook from $400.000 million-$415.000 million to $425.000 million-$428.000 mi...
																	
																	BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $125 to $140.